Founder & Editor
Alex Price is the founder & editor of Undiluted. Having previously built and sold an agency and media business to a debt financed roll up, he launched Undiluted in 2026. Alex talks with funds, banks, advisors and others across the growth lending ecosystem daily.
LinkedIn (opens in a new tab)The Massachusetts AI data platform company will use the scale-up debt financing to expand engineering and cloud-provider coverage as agentic AI workloads move toward production.
1 min read24 Sept 2026The financing comprises a $400m term loan and a $50m revolving credit facility, with proceeds going to existing shareholders, including current and former employees with equity, rather than growth capital.
1 min read23 Sept 2026The compliance management SaaS provider will use the financing to accelerate product development, AI initiatives and technology team expansion, extending a lending relationship that began in 2020.
1 min read23 Sept 2026The San Jose motion-gaming company’s new financing includes a Series E co-led by Baillie Gifford and BAI Capital, with proceeds earmarked for retail, content and international expansion.
1 min read21 Sept 2026Catalio also led a $30m equity financing as part of a $45m package for the Boston medical aesthetics company. UBS Investment Bank and Oak Hill Securities advised AVAVA.
1 min read21 Sept 2026Crunchbase News report the launch of The New York fintech, backed by a Monashees-led seed round and General Catalyst’s Customer Value Fund.
2 min read18 Sept 2026The Nashville merchant services company will use the non-dilutive capital for sales, technology and partnerships as it expands across payments.
1 min read15 Sept 2026Commitments more than doubled the earlier target, with Nvidia able to lease unused GPU capacity for up to six years under a revenue-sharing arrangement.
1 min read14 Sept 2026The UK bank package is separate from Perk’s $300 million private credit facility led by Neuberger Specialty Finance in June.
1 min read14 Sept 2026The Houston CNS oncology company will use the royalty-based financing to scale its CNSide cerebrospinal fluid assay and said cash runway now extends into 2028.
1 min read11 Sept 2026